Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | August 06, 2026 | August 11, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director · Chairman | April 30, 2026 | May 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 400 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 400 · Balance 400 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Exercise / conversion · Disposed 400 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
Emergent BioSolutions Inc.
Report date April 30, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 149,076 |
Reported balance
After 2026-04-30 transaction · row 1
1 source rowRow 1 · 2026-04-30 · Grant · Acquired 25,344 · Balance 149,076 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2033-04-30 | Direct | 11,296 |
Reported balance
After 2026-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-30 · Grant · Acquired 11,296 · Balance 11,296 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2017 Filed May 26, 2017 18:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022490 · doc1.xml · nonDerivative · entry 4 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,077 F4 · security: Consists of restricted stock units granted under the Fourth Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan. F5 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of (i) the anniversary of the date of grant or (ii) one business day prior to date of the Company's next annual meeting; provided that the individual is serving on the Board on such date. Read SEC document |
| August 01, 2016 Filed May 26, 2017 18:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 301 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-022490 · doc1.xml · derivative · entry 5 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,434 Underlying: Common Stock · 3,434 shares Expires 2021-05-21 F6 · security: Consists of an option granted on May 22, 2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F7 · derivative.exercise_date: In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of stock options as a result of an adjustment to an existing Emergent stock option grant held by the reporting person prior to the Spin-off. The stock options vest in May 2017. Read SEC document |
| August 01, 2016 Filed May 26, 2017 18:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 577 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022490 · doc1.xml · nonDerivative · entry 3 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017, May 2018 and May 2019. Read SEC document |
| August 01, 2016 Filed May 26, 2017 18:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022490 · doc1.xml · nonDerivative · entry 2 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,241 F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017 and May 2018. Read SEC document |
| August 01, 2016 Filed May 26, 2017 18:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 152 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022490 · doc1.xml · nonDerivative · entry 1 Harsanyi Zsolt · CIK 0001380184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,637 F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in May 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.